0 CHECKOUT

Sedation - Pipeline Review, H2 2015

  • ID: 3384955
  • July 2015
  • 61 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advicenne Pharma
  • AstraZeneca Plc
  • Paion AG
  • The Medicines Company
  • MORE

Sedation - Pipeline Review, H2 2015

Summary

The report ‘Sedation - Pipeline Review, H2 2015’, provides an overview of the Sedation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advicenne Pharma
  • AstraZeneca Plc
  • Paion AG
  • The Medicines Company
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Sedation Overview
Therapeutics Development
Pipeline Products for Sedation - Overview
Pipeline Products for Sedation - Comparative Analysis
Sedation - Therapeutics under Development by Companies
Sedation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Sedation - Products under Development by Companies
Sedation - Companies Involved in Therapeutics Development
Advicenne Pharma
AstraZeneca Plc
Concert Pharmaceuticals, Inc.
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Nhwa Pharma Corporation
NanoMedex Pharmaceuticals, Inc.
Paion AG
The Medicines Company
Sedation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABP-700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADV-6209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alphaxalone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTP-354 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol microemulsion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sedation - Recent Pipeline Updates
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward
Mar 31, 2015: PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials
Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids
Jun 18, 2014: Drawbridge Pharmaceuticals granted new anaesthesia patent for Phaxan in China
Apr 16, 2014: Drawbridge Pharmaceuticals announces successful clinical trial results for Phaxan and grant of US patent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sedation, H2 2015
Number of Products under Development for Sedation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Sedation - Pipeline by Advicenne Pharma, H2 2015
Sedation - Pipeline by AstraZeneca Plc, H2 2015
Sedation - Pipeline by Concert Pharmaceuticals, Inc., H2 2015
Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2015
Sedation - Pipeline by Jiangsu Nhwa Pharma Corporation, H2 2015
Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2015
Sedation - Pipeline by Paion AG, H2 2015
Sedation - Pipeline by The Medicines Company, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Sedation Therapeutics - Recent Pipeline Updates, H2 2015
Sedation - Dormant Projects, H2 2015
Sedation - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Sedation, H2 2015
Number of Products under Development for Sedation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Advicenne Pharma
AstraZeneca Plc
Concert Pharmaceuticals, Inc.
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Nhwa Pharma Corporation
NanoMedex Pharmaceuticals, Inc.
Paion AG
The Medicines Company

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Baxter International Inc.
  • Purdue Pharma L.P.
  • Hikma Pharmaceuticals PLC
  • Eisai Co
  • Astrazeneca PLC
  • Mylan N.V.